|
Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8 (6):639-646. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Fili, S. Ferri, F. Frosali, F. Giudici, P. Romagnani, P. Parronchi, F. Tonelli, E. Maggi, and S. Romagnani. 2007. Phenotypic and functional features of human Th17 cells. J Exp Med 204 (8):1849-1861. Baecher-Allan, C., J. A. Brown, G. J. Freeman, and D. A. Hafler. 2001. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167 (3):1245-1253. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautes-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour. 2002a. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99 (6):2114-2121. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Saut癡s-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour. 2002b. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99 (6):2114-2121. Bettelli, E., M. Oukka, and V. K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8 (4):345-350. Campbell, D. J., and S. F. Ziegler. 2007. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 7 (4):305-310. Chin, D., G. M. Boyle, S. Porceddu, D. R. Theile, P. G. Parsons, and W. B. Coman. 2006. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 6 (7):1111-1118. Cosmi, L., F. Liotta, E. Lazzeri, M. Francalanci, R. Angeli, B. Mazzinghi, V. Santarlasci, R. Manetti, V. Vanini, P. Romagnani, E. Maggi, S. Romagnani, and F. Annunziato. 2003. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 102 (12):4107-4114. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, and W. Zou. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (9):942-949. Hirahara, N., Y. Nio, S. Sasaki, Y. Minari, M. Takamura, C. Iguchi, M. Dong, K. Yamasawa, and K. Tamura. 2001. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61 (1):79-89. Kiniwa, Y., Y. Miyahara, H. Y. Wang, W. Peng, G. Peng, T. M. Wheeler, T. C. Thompson, L. J. Old, and R. F. Wang. 2007. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13 (23):6947-6958. Knutson, K. L., M. L. Disis, and L. G. Salazar. 2007. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 56 (3):271-285. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity 21 (4):467-476. Kondo, T., H. Takata, F. Matsuki, and M. Takiguchi. 2009. Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 182 (4):1794-1798. Kono, K., H. Kawaida, A. Takahashi, H. Sugai, K. Mimura, N. Miyagawa, H. Omata, and H. Fujii. 2006. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55 (9):1064-1071. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178 (11):6730-6733. Lin, W. W., and M. Karin. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (5):1175-1183. Liotta, F., L. Cosmi, P. Romagnani, E. Maggi, S. Romagnani, and F. Annunziato. 2005. Functional features of human CD25+ regulatory thymocytes. Microbes and Infection 7 (7-8):1017-1022. Liu, S. J., J. P. Tsai, C. R. Shen, Y. P. Sher, C. L. Hsieh, Y. C. Yeh, A. H. Chou, S. R. Chang, K. N. Hsiao, F. W. Yu, and H. W. Chen. 2007. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol 82 (2):354-360. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. In Nature, 231-234. Mills, K. H. 2008. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38 (10):2636-2649. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14 (2):155-174. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. W. Kerstann, L. Feigenbaum, C. C. Chan, and N. P. Restifo. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2):362-373. Numasaki, M., J. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze. 2003a. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (7):2620-2627. Numasaki, M., J. I. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze. 2003b. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (7):2620-2627. Numasaki, M., M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, and H. Sasaki. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175 (9):6177-6189. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (11):1133-1141. Shevach, E. M. 2006. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 (2):195-201. Singh, S. P., H. H. Zhang, J. F. Foley, M. N. Hedrick, and J. M. Farber. 2008. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180 (1):214-221. Steiner, G. E., M. E. Newman, D. Paikl, U. Stix, N. Memaran-Dagda, C. Lee, and M. J. Marberger. 2003. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56 (3):171-182. Strauss, L., C. Bergmann, W. Gooding, J. T. Johnson, and T. L. Whiteside. 2007. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 (21):6301-6311. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2):179-189. von Boehmer, H. 2005. Mechanisms of suppression by suppressor T cells. Nat Immunol 6 (4):338-344. Voo, K. S., Y. H. Wang, F. R. Santori, C. Boggiano, K. Arima, L. Bover, S. Hanabuchi, J. Khalili, E. Marinova, B. Zheng, D. R. Littman, and Y. J. Liu. 2009. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 106 (12):4793-4798. Walsh, J. E., D. M. Lathers, A. C. Chi, M. B. Gillespie, T. A. Day, and M. R. Young. 2007. Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol 8 (3):227-238. Wraith, D. C. 2006. Anti-cytokine vaccines and the immunotherapy of autoimmune diseases. Eur J Immunol 36 (11):2844-2848. Yang, L., D. E. Anderson, C. Baecher-Allan, W. D. Hastings, E. Bettelli, M. Oukka, V. K. Kuchroo, and D. A. Hafler. 2008. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454 (7202):350-352. Yokokawa, J., V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang. 2008. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14 (4):1032-1040. Young, M. R. 2006. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28 (5):462-470. Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, and G. Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374 (3):533-537. Zhou, L., J. E. Lopes, M. M. Chong, Ivanov, II, R. Min, G. D. Victora, Y. Shen, J. Du, Y. P. Rubtsov, A. Y. Rudensky, S. F. Ziegler, and D. R. Littman. 2008. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453 (7192):236-240. 行政院衛生署統計資料 2007
|